The viral-infection-mediated release of HMGB1 triggers pro-inflammatory responses similar to those of LPS and thus supports the significance of the therapeutic potential of TLR4/MD-2 antagonists for symptom release in viral disease. Here, LY96 is linked to viral infectious disease.